Next-gen RNAi drugmaker City prices $200M IPO
BioPharma DiveDelilah AlvaradoOctober 16, 2026
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.